Chris Lau

Chris Lau

InvestorPlace Contributor

Expertise: Technology, Biotech

Expertise:

Technology
Biotech

Education:

Bachelor of Science
Project Management Professional

Awards and Accomplishments:

Top 100 Tipranks 2015-2021

About Chris:

Chris has over two decades of investing experience. He is an Honors B.Sc graduate (with distinction) in Science and Economics. He holds a Project Management Professional designation

Chris focuses on the technology, cyclical, and healthcare sector. He runs a newsletter with speculative Triple-baggers.

His investment strategy is based on finding undervalued stocks trading at a steep discount to their intrinsic value.

Follow Chris on DIY Value Investing.

Recent Articles

Heat Biologics Stock Is a Worthwhile, Speculative Bet

By Chris Lau, InvestorPlace Contributor

Heat Biologics has a partnership with Bristol-Myers in developing a cancer drug. If things continue to progress positively, HTBX stock could climb higher.

Why Xenetic Biosciences Just Surged 28 Percent

By Chris Lau, InvestorPlace Contributor

Xenetic Biosciences surged once again on a spike in volume. Could XBIO stock rally more and hold on to gains this time around?

GlycoMimetics Stock Has Substantial Upside

By Chris Lau, InvestorPlace Contributor

GlycoMimetics reported no surprises and even beat consensus estimates on earnings. The company has many drugs in clinical trials for treating cancer, AML and MM.

What to Do After Cutera Stock Fell 16.7%

By Chris Lau, InvestorPlace Contributor

CUTR stock has reached attractive levels, as it has a strong, new product, and its investments will improve its business. Value investors should look to buy shares of Cutera.

Protagonist Stock Jumps 58% After Re-Review of Test Results

By Chris Lau, InvestorPlace Contributor

A re-review of the PTG-100 results undid the bad news of a discontinuation of Protagonist's clinical study. If the FDA allows the company to run Phase 2/3 studies for PTG-100, then the stock will continue its bounce higher.

OPKO Stock Had a Great Q2 and the Future Looks Even Better

By Chris Lau, InvestorPlace Contributor

With shares nearly double where they were in May, OPKO Health, Inc. (NASDAQ:OPK) needed a strong second-quarter earnings report to justify the gains in OPKO…

After the Dip, Symantec Stock Could Have at Least 30% Upside

By Chris Lau, InvestorPlace Contributor

Symantec missed analyst forecasts and lowered its current second quarter outlook. Business will underperform for the rest of the fiscal year, but things look brighter for SYMC stock by fiscal year 2020.

Mazor Robotics Is Still Expensive Despite Recent Drop

By Chris Lau, InvestorPlace Contributor

Investors expected more from Mazor Robotics and the company failed to deliver. The Medtronic distribution deal is to blame. Will business improve?

All the Good News (And Then Some) Already Is Priced into Abiomed Stock

By Chris Lau, InvestorPlace Contributor

Abiomed stock is down 10 percent following first-quarter earnings. The company exceeded expectations and reported growth in the triple digits. So what gives? The good news is priced in.

Why Every Investor Should Hold Shares of Biogen Stock

By Chris Lau, InvestorPlace Contributor

Biogen reported solid study results for its Alzheimer's study and followed up with a solid quarterly earnings report. BIIB stock is a clear core holding for investors.

Load More